0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Assessment of Apical Hypertrophic Cardiomyopathy Using Transoesophageal Echocardiography

      , ,

      Cardiology

      S. Karger AG

      Echocardiography, Cardiomyopathy, Hypertrophy

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Two-dimensional echocardiography is the method of choice for imaging and diagnosis in patients with hypertrophic cardiomyopathy. However, ultrasound examination of the left ventricular apex by transthoracic echocardiography is often inadequate so that hypertrophy localised to this region may be missed. The purpose of this study was to evaluate the use of multiplane transoesophageal echocardiography in the diagnosis and assessment of apical hypertrophic cardiomyopathy. Six patients with apical hypertrophic cardiomyopathy underwent transthoracic and multiple transoesophageal echocardiography. Assessment of the proximal left ventricle was possible in all patients by both techniques and normal wall thickness measurements were obtained. Assessment of the distal left ventricle by multiple transesophageal echococardiography revealed hypertrophy of the apex (range 1.7-2.9 cm) and less marked hypertrophy of the distal segments of the left ventricle in all 6 patients (1.4-2.2 cm). Examination of the papillary muscles was also possible and hypertrophy was detected in 2 patients. By transthoracic echocardiography, hypertrophy was detected in the distal left ventricle of 5 patients and values were less than those obtained by multiplane transoesophageal echocardiography. No papillary muscle hypertrophy was seen. The apical segment was imaged in only 4 patients and maximum thicknesses of the apical segment were greater by multiple transoesophageal echocardiographic examination than by transthoracic echocardiography (mean 2.25 ± 0.4 and 1.97 ± 0.3 cm, respectively). We conclude that apical hypertrophic cardiomyopathy may be difficult to diagnose using transthoracic echocardiography because of inconsistent imaging of the apical segment. The distribution of hypertrophy may be inappropriately assigned and the severity of wall thickening underestimated. Multiplane transoesophageal echocardiography allows high resolution imaging of all segments of the left ventricle, particularly the apex.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1997
          1997
          19 November 2008
          : 88
          : 2
          : 189-196
          Affiliations
          Regional Cardiac Unit, Papworth Hospital Cambridge, UK
          Article
          177328 Cardiology 1997;88:189–196
          10.1159/000177328
          9096921
          © 1997 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8
          Categories
          Noninvasive and Diagnostic Cardiology

          Comments

          Comment on this article